“This launch delivers on our strategy to continue to build our hospital and clinic portfolio and provide US patients access to affordable generic medicines that work as well as brand-name products.” “As the first generic high dose IV iron available in the US, Ferumoxytol provides patients with iron deficiency anemia a more cost-effective treatment option,” said Keren Haruvi, President, Sandoz Inc. 2 The overall global IV iron market is over a one billion dollar market and continues to grow. Princeton, New Jersey, JSandoz, a global leader in generic and biosimilar medicines, today announced the immediate US availability of generic Ferumoxytol, an intravenous medicine used to treat iron deficiency anemia (IDA).įerumoxytol, a generic equivalent to AMAG Pharmaceuticals’ Feraheme ®* (ferumoxytol injection), is approved to treat IDA in adult patients who have an intolerance to oral iron or have had an unsatisfactory response to oral iron, or who have chronic kidney disease.
Immediate availability of Ferumoxytol Injection bolsters Sandoz portfolio and delivers another high-quality generic medicine to US patients.Iron deficiency anemia occurs when there is a lower than normal number of oxygen-carrying red blood cells because of too little iron 1.Patients with iron deficiency anemia in a hospital or clinic setting now have access to an important IV iron medicine at a more affordable price.